Drug Trial Radar · NCT07362030
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Actual
Start
Apr 14, 2025
Primary completion
Dec 27, 2025
Study completion Mar 30, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and
Conditions
- Obesity
Interventions
RAY1225Drug
subcutaneous injection
atorvastatin calcium tabletDrug
Oral
Metformin TabletsDrug
Oral
Warfarin Sodium TabletsDrug
Oral
Digoxin TabletsDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic - CmaxTime frame: Day 1~Day 5 and Day 86~Day 107
- Pharmacokinetic -Area under the curve(AUC)Time frame: Day 1~Day 5 and Day 86~Day 107
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dongguan People's Hospital
Dongguan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.